Today's arsenal of antibiotics is ineffective against some emerging strains of antibiotic-resistant pathogens. Novel inhibitors of bacterial growth therefore need to be found. The target of such bacterialgrowth inhibitors must be identified, and one way to achieve this is by locating mutations that suppress their inhibitory effect. Here, we identified five growth inhibitors encoded by T7 bacteriophage. High-throughput sequencing of genomic DNA of resistant bacterial mutants evolving against three of these inhibitors revealed unique mutations in three specific genes. We found that a nonessential host gene, ppiB, is required for growth inhibition by one bacteriophage inhibitor and another nonessential gene, pcnB, is required for growth inhibition by a different inhibitor. Notably, we found a previously unidentified growth inhibitor, gene product (Gp) 0.6, that interacts with the essential cytoskeleton protein MreB and inhibits its function. We further identified mutations in two distinct regions in the mreB gene that overcome this inhibition. Bacterial two-hybrid assay and accumulation of Gp0.6 only in MreB-expressing bacteria confirmed interaction of MreB and Gp0.6. Expression of Gp0.6 resulted in lemon-shaped bacteria followed by cell lysis, as previously reported for MreB inhibitors. The described approach may be extended for the identification of new growth inhibitors and their targets across bacterial species and in higher organisms. in some bacteria, the resistance mechanisms against most conventional antibiotics have been identified (1, 2). This increasing threat is spurring the identification of novel antimicrobials against novel molecular targets in the pathogens (e.g., refs. 3-6). There are currently only a few host molecules targeted by antibiotics. These targets (and examples of the antibiotics against them) are host RNA polymerase (rifampicin), topoisomerase (quinolones), cell wall (penicillin), membranes (polymyxin), ribosome (tetracyclines, aminoglycosides, macrolids), and synthesis of nucleic-acid precursors (sulfonamides, trimethoprim). Increasing the arsenal of bacterial targets and antimicrobial drugs against them is valuable, and novel strategies to increase this repertoire are therefore of great importance.One strategy for the identification of novel antibacterial targets is to determine how bacteriophages shut down their host's biosynthetic pathways and enslave its machinery during infection. Phages have coevolved with bacteria for over 3 billion years and have thus developed molecules to specifically and optimally inhibit or divert key metabolic functions. Examples of bacterial targets inhibited by phage-derived products include the δ subunit of the DNA polymerase III clamp loader, inhibited by gene product (Gp) 8 of the coliphage N4 (7); the Staphylococcus aureus putative helicase loader, DnaI, inhibited by ORF104 of bacteriophage 77 (5); a key enzyme of folate metabolism, FolD, inhibited by Gp55.1 of the coliphage T4 (8); and the essential cell-division protein, filamenting temperature-sen...